Table 2.
Prevalence of specific anti-phospholipid antibodies in the different study groups
| Study groups (n = 104) | % (Number of positive cases per group) | |||
|---|---|---|---|---|
| LAC | aCL IgG and/or IgM | aβ2GPI IgG and/or IgM | aPS/PT IgG and/or IgM | |
| Primary APS (n = 8) | 87·5 (7/8) | 25 (2/8) | 25 (2/8) | 62·5 (5/8) |
| Secondary APS (n = 3) | 66·7 (2/3) | 33·3 (1/3) | 33·3 (1/3) | 33·3 (1/3) |
| SLE (n = 5) | 0 | 0 | 0 | 0 |
| Non-SLE autoimmune diseases (n = 11) | 9·1 (1/11) | 9·1 (1/11) | 9·1 (1/11) | 27·3 (3/11) |
| Inherited thrombophilia (n = 2) | 0 | 0 | 0 | 0 |
| Idiopathic thrombosis (n = 15) | 0 | 0 | 0 | 0 |
| Equivocal LAC with APS manifestations (n = 8) | 0 | 0 | 0 | 12·5 (1/8) |
| Any PRM with negative criteria laboratory tests for APS (n = 8) | 0 | 0 | 0 | 0 |
| Other clinical conditions (n = 44) | 9·1 (4/44) | 9·1 (4/44) | 2·3 (1/44) | 13·7 (6/44) |
| Overall | 13·5 (14/104) | 7·7 (8/104) | 4·8 (5/104) | 15·4 (16/104) |
APS = anti-phospholipid syndrome; LAC = lupus anti-coagulant; aCL = anti-cardiolipin; aβ2GPI = anti-beta2 glycoprotein I; aPS/PT = anti-phosphatidylserine/prothrombin complex; PRM = pregnancy-related mortality; SLE = systemic lupus erythematosus; Ig = immunoglobulin.